Novartis Says FDA Approves Cosentyx to Treat Some Children, Adolescents With Arthritis
December 22 2021 - 6:59PM
Dow Jones News
By Stephen Nakrosis
Novartis AG on Wednesday said the U.S. Food and Drug
Administration approved Cosentyx as a treatment for certain
children and adolescents with arthritis.
The company said Cosentyx, or secukinumab, was approved to treat
active enthesitis-related arthritis, or ERS, in those 4 and older.
Cosentyx was also approved as a treatment for active juvenile
psoriatic arthritis, or JPsA, in those 2 and older.
According to Novartis, "Cosentyx is now the first biologic
indicated for ERA, and the only biologic treatment approved for
both ERA and PsA in pediatric patients in the U.S."
The company said the latest approvals are the second and third
for Cosentyx in a pediatric population in the U.S., and added
Cosentyx now has a total of five indications across rheumatology
and dermatology.
Novartis also said it filed a regulatory submission for Cosentyx
in ERA and JPsA in Europe, and expects a decision in coming
months.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
December 22, 2021 18:44 ET (23:44 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Novartis (NYSE:NVS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Novartis (NYSE:NVS)
Historical Stock Chart
From Apr 2023 to Apr 2024
